Characterization of 2-chloro-N10-substituted phenoxazines for reversing multidrug resistance in cancer cells

Oncology Research

Volumn 10, Issue 1, 1998, Pages 29-41

  Thimmaiah, Kuntebommanahalli N ^a   Jayashree, Bellur S ^a   Germain, Glen S ^b   Houghton, Peter J ^b   Horton, Julie K ^c,d  

^a UNIVERSITY OF MYSORE   (India)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^d NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

Multidrug resistance; P glycoprotein; Resistance modulators

Indexed keywords

ADENOSINE TRIPHOSPHATASE; CHLORINE; COLCHICINE; GLYCOPROTEIN P; OXAZINE DERIVATIVE; PACLITAXEL; VINBLASTINE;

ADENOCARCINOMA; ARTICLE; CELL CLONE; CELL CULTURE; CELL STRAIN KB; CHEMICAL STRUCTURE; CHEMISTRY; COLON TUMOR; HUMAN; METABOLISM; MULTIDRUG RESISTANCE; REGRESSION ANALYSIS; STRUCTURE ACTIVITY RELATION;

ADENOCARCINOMA; ADENOSINE TRIPHOSPHATASES; CHLORINE; CLONE CELLS; COLCHICINE; COLONIC NEOPLASMS; DRUG RESISTANCE, MULTIPLE; HUMANS; KB CELLS; MOLECULAR STRUCTURE; OXAZINES; P-GLYCOPROTEIN; PACLITAXEL; REGRESSION ANALYSIS; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED; VINBLASTINE;

EID: 0031609835     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. DeVita, V T. Principles of chemotherapy. Philadelphia: J. B. Lippincott Company; 1993.
2. Gottesman, M. M.; Pastan, I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 62: 385-427; 1993.
3. Cornwell, M.; Tsuruo, T.; Gottesman.; M. Pastan, I. ATP-binding properties of P glycoprotein from multidrug-resistant KB cells. FASEB J. 1:51-54; 1987.
4. Safa, A. R.; Glover, C. J.; Meyers, M. B.; Biedler, J. L.; Felsted, R. L. Vinblastine photoaffinity labeling of a high molecular weight surface membrane glycoprotein specific for multidrug-resistant cells. J. Biol. Chem. 261:6137-6140; 1986.
5. Senior, A. E.; Al-Shawi, M. K.; Urbatsch, I. L. ATP hydrolysis by multidrug-resistance protein from Chinese hamster ovary cells. J. Bioenerg. Biomembr. 27:31-36; 1995.
6. Sharom, F. J. Characterization and functional reconstitution of the multidrug transporter. J. Bioenerg. Biomembr. 27:15-22; 1995.
7. Ford, J. M. Modulators of multidrug resistance. Hematol. Oncol. Clin. North Am. 9:337-361; 1995.
8. Tsuruo, T.; Iida, H.; Tsukagoshi, S.; Sakurai, Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res. 41:1967-1972; 1981.
9. Ganapathi, R.; Grabowski, D. Enhancement of sensitivity to adriamycin in resistant P388 leukemia by the calmodulin inhibitor trifluoperazine. Cancer Res. 43:3696-3699; 1983.
10. Chauffert, B.; Rey, D.; Coudert, B.; Dumas, M.; Martin F. Amiodarone is more efficient than verapamil in reversing resistance to anthracyclines in tumour cells. Br. J. Cancer 56:119-122; 1987.
11. Zamora, J. M.; Beck, W. T. Chloroquine enhancement of anticancer drug cytotoxicity in multiple drug resistant human leukemic cells. Biochem. Pharamcol. 35:4303-4310; 1986.
12. Ford, J. M.; Prozialeck, W. C.; Hait, W. N. Structural features determining activity of phenothiazines and related drugs for inhibition of cell growth and reversal of multidrug resistance. Mol. Pharmacol. 35:105-115; 1989.
13. Ford, J. M.; Bruggemann, E. P.; Pastan, I.; Gottesman, M. M.; Hait, W. N. Cellular and biochemical characterization of thioxanthenes for reversal of multidrug resistance in human and murine cell lines. Cancer Res. 50:1748-1756; 1990.
14. Ramu, A.; Glaubiger, D.; Fuks, Z. Reversal of acquired resistance to doxorubicin in P388 murine leukemia cells by tamoxifen and other triparanol analogues. Cancer Res. 44:4392-4395; 1984.
15. Twentyman, P. R. Cyclosporins as drug resistance modifiers. Biochem. Pharmacol. 43:109-117; 1992.
16. te Boekhorst, P. A.; van Kapel, J.; Schoester, M.; Sonneveld, P. Reversal of typical multidrug resistance by cyclosporin and its non-immunosuppressive analogue SDZ PSC 833 in Chinese hamster ovary cells expressing the mdr1 phenotype. Cancer Chemother. Pharmacol. 30:238-242; 1992.
17. Liu, Z.; Lheureux, F.; Pouliot, J.-F.; Heckel, A.; Bamberger, U.; Georges, E. BIBW22 BS, a potent multidrug resistance-reversing agent, binds directly to P-glycoprotein and accumulates in drug-resistant cells. Mol. Pharmacol. 50:482-492; 1996.
18. Dantzig, A. H.; Shephard, R. L.; Cao, J.; Law, K. L.; Ehlhardt, W. J.; Baughman, T. M.; Bumol, T. F.; Starling, J. J. Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. Cancer Res. 56: 4171-4179; 1996.
19. Yusa, K.; Tsuruo, T. Reversal mechanism of multidrug resistance by verapamil: Direct binding of verapamil to P-glycoprotein on specfic sites and transport of verapamil outward across the plasma membrane of K562/ADM cells. Cancer Res. 49:5002-5006; 1989.
20. Scala, S.; Akhmed, N.; Rao, U. S.; Paull, K.; Lan, L.-B.; Dickstein, B.; Lee, J.-S.; Elgemeie, G. H.; Stein, W.; Bates, S. E. P-glycoprotein substrates and antagonists cluster into two distinct groups. Mol. Pharmacol. 51:1024-1033; 1997.
21. Bain, L. J.; McLachlan, J. B.; LeBlanc, G. A. Structure-activity relationships for xenobiotic transport substrates and inhibitory ligands of P-glycoprotein. Environ. Health Perspect. 105:812-818; 1997.
22. Goldstein, L. J. Clinical reversal of drug resistance. Curr. Prob. Cancer 19:65-124; 1995.
23. Ozols, R. F.; Cunnion, R. E.; Klecker, R. W., Jr.; Hamilton, T. C.; Ostchega, Y.; Parrillo, J. E.; Young, R. C. Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients. J. Clin. Oncol. 5:641-647; 1987.
24. Ford, J. M.; Hait, W. N. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol. Rev. 42:155-199; 1990.
25. List, A. F.; Spier, C.; Greer, J.; Wolff, S.; Hutter, J.; Dorr, R.; Salmon, S.; Futscher, B.; Baier, M.; Dalton, W. Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. J. Clin. Oncol. 11:1652-1660; 1993.
26. Warner, E.; Tobe, S. W.; Andrulis, I. L.; Pei, Y.; Trachtenberg, J.; Skorecki, K. L. Phase I-II study of vinblastine and oral cyclosporin A in metastatic renal cell carcinoma. Am. J. Clin. Oncol. 18:251-256; 1995.
27. Boote, D. J.; Dennis, P. R.; Twentyman, P. R.; Osborne, R. J.; Laburte, C.; Hensel, S.; Smyth, J. F.; Brampton, M. H.; Bleehan, N. M. Phase I study with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer. J. Clin. Oncol. 14:610-618; 1996.
28. Fisher, G. A.; Hausdorff, J.; Lum, B. L.; Pearce, T.; Halsey, J.; Sikic, B. I. Phase I trial of paclitaxel in combination with SDZ PSC 833, a multidrug resistance modulator. Proc. Am. Soc. Clin. Oncol. 14:181; 1995.
29. Thimmaiah, K. N.; Horton, J. K.; Qian, X.-d.; Beck, W. T.; Houghton, J. A.; Houghton, P. J. Structural determinants of phenoxazine type compounds required to modulate the accumulation of vinblastine and vincristine in multidrug-resistant cell lines. Cancer Commun. 2:249-259; 1990.
30. Thimmaiah, K. N.; Horton, J. K.; Seshadri, R.; Israel, M.; Houghton, J. A.; Harwood, F. C.; Houghton, P. J. Synthesis and chemical characterization of N-substituted phenoxazines directed toward reversing Vinca alkaloid resistance in multidrug-resistant cancer cells. J. Med. Chem. 35:3358-3364; 1992.
31. Horton, J. K.; Thimmaiah, K. N.; Harwood, F. C.; Kuttesch, J. D.; Houghton, P. J. Pharmacological characterization of N-substituted phenoxazines directed toward reversing Vinca alkaloid resistance in multidrug-resistant cancer cells. Mol. Pharmacol. 44:552-559; 1993.
32. Shen, D.-w.; Fojo, A.; Chin, J. E.; Roninson, I. B.; Richert, N.; Pastan, I.; Gottesman, M. M. Human multidrug-resistant cell lines: Increased expression can precede gene amplification. Science 232: 643-645; 1986.
33. Houghton, P. J.; Germain, G. S.; Hazelton, B. J.; Pennington, J. W.; Houghton, J. A. Mutants of human colon adenocarcinoma cells selected for thymidylate synthase deficiency. Proc. Natl. Acad. Sci. USA 86:1377-1381; 1989.
34. Fairchild, C. R.; Moscow, J. A.; O'Brien, E. E.; Cowan, K. H. Multidrug resistance in cells transfected with human genes encoding a variant P-glycoprotein and glutathione S-transferase-π. Mol. Pharmacol. 37:801-809; 1990.
35. Butler, W. B. Preparing nuclei from cells in monolayer cultures suitable for counting and for following synchronized cells through the cell cycle. Anal. Biochem. 141:70-73; 1984.
36. Owellen, R. J.; Donigian, D. W.; Hartke, C. A.; Hains, F. O. Correlation of biologic data with physicochemical properties among the Vinca alkaloids and their congeners. Biochem. Pharmacol. 26: 1213-1219; 1977.
37. Zamora, J. M.; Pearce, H. L.; Beck, W. T. Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells. Mol. Pharmacol. 33:454-462; 1988.
38. Pourcher, T.; Altenberg, G. A.; Reuss, L. Heterologous expression of human P-glycoprotein (Pgp) using bacterial and baculovirus expression systems. FASEB J. 10:A92; 1996.
39. Altenberg, G. A.; Subramanyam, M.; Reuss, L. Muscarinic stimulation of gallbladder epithelium III. Antagonism of cAMP-mediated effects. Am. J. Physiol. 267:C1196-C1202; 1994.
40. Sarkadi, B.; Price, E. M.; Boucher, R. C.; Germann, U. A.; Scarborough, G. A. Expression of the human multidrug resistance cDNA in insect cells generates a high activity drug-stimulated membrane ATPase. J. Biol. Chem. 267:4854-4858; 1992.
41. Schneider, E.; Horton, J. K.; Yang, C.-h.; Nakagawa, M.; Cowan, K. H. Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance. Cancer Res. 54:152-158; 1994.
42. Ambudkar, S. V. Purification and reconstitution of functional human P-glycoprotein. J. Bioenerg. Biomembr. 27:23-29; 1995.
43. De Duve, C.; De Barsy, T.; Poole, B.; Trouet, A.; Tukens, P.; Van Hoof, F. Lysosomotropic agents. Biochem. Pharmacol. 23: 2495-2531; 1974.
44. Chiba, P.; Ecker, G.; Schmid, D.; Drach, J.; Tell, B.; Goldenberg, S.; Gekeler, V. Structural requirements for activity of propafenone-type modulators in P-glycoprotein-mediated multidrug resistance. Mol. Pharmacol. 49:122-1130; 1996.
45. Ecker, G.; Chiba, P.; Hitzler, M.; Schmid, D.; Visser, K.; Cordes, H. P.; Csollei, J.; Seydel, J. K.; Schaper, K.-J. Structure-activity relationship studies on benzofuran analogs of propafenone-type modulators of tumor cell multidrug resistance. J. Med. Chem. 39: 4767-4774; 1996.
46. Kanaho, Y.; Sato, T.; Fujii, T. The affinity of various phenothiazine drugs for membranes of intact human erythrocytes and their membrane-transforming activity. Mol. Pharmacol. 20:704-708; 1981.
47. Horio, M.; Gottesman, M. M.; Pastan, I. ATP-dependent transport of vinblastine in vesicles from human multidrug-resistant cells. Proc. Natl. Acad. Sci. USA 85:3580-3584; 1988.
48. Motohashi, N.; Mitscher, L. A.; Meyer, R. Potential antitumor phenoxazines. Med. Res. Rev. 11:239-294; 1991.
49. Ramu, N.; Ramu, A. Circumvention of adriamycin resistance by dipyridamole analogues: A structure-relationship study. Int. J. Cancer 43:487-491; 1989.